Poolbeg Pharma Plc is a clinical-stage biopharmaceutical company, which focuses on the development of innovative medicines to address unmet medical needs. The firm is focused on the development of medicines to address unmet medical needs. Its clinical programmes target addressable markets, including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions, such as obesity with the development of an oral encapsulated glucagon-like peptide (GLP-1R) agonist. Its pipeline includes POLB 001 Oncology, POLB 001 Influenza, AI Programmes and Oral Encapsulated GLP-1programme. POLB 001 is an orally delivered p38 MAP Kinase inhibitor being developed for the prevention of CRS associated with Bispecific Antibodies and CAR T immunotherapy treatments in cancer. The company uses artificial intelligence to identify infectious disease drug targets & treatments. The Oral Encapsulated GLP-1 programme leverages an advanced delivery system that encapsulates active pharmaceutical ingredients using Generally Regarded as Safe (GRAS) components.
Follow-Up Questions
Qui est le CEO de Poolbeg Pharma PLC ?
Dr. Jeremy Skillington est le Chief Executive Officer de Poolbeg Pharma PLC, il a rejoint l'entreprise depuis 2021.
Quelle est la performance du prix de l'action POLBF ?
Le prix actuel de POLBF est de $0, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Poolbeg Pharma PLC ?
Poolbeg Pharma PLC appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quelle est la capitalisation boursière de Poolbeg Pharma PLC ?
La capitalisation boursière actuelle de Poolbeg Pharma PLC est de $0
Est-ce que Poolbeg Pharma PLC est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 5 analystes ont établi des notations d'analystes pour Poolbeg Pharma PLC, y compris 1 achat fort, 3 achat, 1 maintien, 0 vente et 1 vente forte
